Local partner Carnot, marketing and sales in Central and South America, excluding Brazil
Completed expansion into 18 Central and South American countries
Local medical staff academic conference held… Launch in 6 countries within the year
Settling into the Mexican market… Top 10 in 7 months
“Next year, our goal is to be number one in sales of digestive medicines in Central and South America”
HK inno.N announced on the 2nd that its new drug for gastroesophageal reflux disease, ‘K-Cap’, has obtained product approval in six Central and South American countries, including Colombia.
The countries where K-CAB (ingredient name: tegoprazan) has been approved this time are Colombia, Dominican Republic, Nicaragua, Honduras, Guatemala, and El Salvador. The local product name is ‘Ki-CAB’. Accordingly, the total number of Central and South American countries where K-CAB has advanced (including technology export) has increased to 18. The product was launched in Mexico and Peru last year, and was recently launched in Chile, and it is said that an official launch in 6 countries is scheduled for this year.
In 17 countries in the Central and South American market, excluding Brazil, K-Cap sales are handled by local partner company ‘Carnot’. Based on active marketing, K-Cap is expanding its base in the Central and South American market. HK inno.N and Carnot have been holding academic conferences for medical professionals in Korea and Central and South America since last year to help K-Cap settle in the local market. This year, medical professionals from Mexico and Colombia visited Korea to share the latest knowledge on K-Cap treatment cases, various treatment options including K-Cap, and the current status of local gastroesophageal reflux disease treatment.
Kwak Dal-won, CEO of HK inno.N, said, “Based on the demand and positive response from the Central and South American markets, we are accelerating our efforts to conquer the Central and South American market with K-Cap,” and “Through this academic conference with medical professionals from Central and South America, we were able to confirm the interest in K-Cap in the Central and South American market.”
Guy Jean Savoir, Chairman of Carnot, said, “K-Cap has settled into the top 10 in the local peptic ulcer treatment market in Mexico in just seven months since its launch, and we expect it to continue growing this year and enter the top 5 in the market,” adding, “Our goal is to launch K-Cap in all contracted countries by next year and achieve the top spot in sales of digestive medicines in Central and South America.”
Meanwhile, HK inno.N K-Cap is a P-CAB series drug considered as a next-generation gastroesophageal reflux disease treatment and is the 30th new drug in Korea. Its efficacy appears quickly within 1 hour after administration and its efficacy and safety have been secured even with long-term administration for up to 6 months. Since its launch in Korea in 2019, it has ranked first in the domestic peptic ulcer treatment market for 4 consecutive years. As of July, the cumulative outpatient prescriptions were tallied at a total of 617.4 billion won.
It is also actively entering overseas markets. It has entered 45 countries including the US and China, and has been officially launched in 9 countries including Korea. In particular, since the Mexican Society of Gastroenterology recently announced guidelines recommending P-CAB series for the early treatment of gastroesophageal reflux disease, it is expected that K-CAP’s influence will grow further in the Central and South American market.
Kim Min-beom, Donga.com reporter [email protected]
-
- great
- 0dog
-
- I’m sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news right now
2024-09-03 03:36:30